Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2011-07-28

AUTHORS

Hiroshi Hasegawa, Hiroyuki Takano, Hiroya Narumi, Masashi Ohtsuka, Tadahiko Mizuguchi, Takao Namiki, Yoshio Kobayashi, Issei Komuro

ABSTRACT

The Telmisartan and Losartan Cardiac Evaluation Trial, a multicenter, prospective, randomized, open-labeled, blinded-endpoint trial, was designed to compare the effects of two angiotensin II receptor blockers (ARBs), telmisartan and losartan, on cardiovascular protection in Japanese patients with mild to moderate essential hypertension. We compared the effects of telmisartan and losartan on left ventricular (LV) hypertrophy, cardiac function, atherosclerosis of carotid arteries and surrogate markers related to the actions of peroxisome proliferator-activated receptor-γ. A total of 58 patients were enrolled in the present trial and the follow-up period was 1 year. There were no significant differences in blood pressure (BP) levels between the telmisartan group and the losartan group throughout the trial. The percentage of the patients treated with ARB monotherapy was significantly higher in the telmisartan group compared with the losartan group. In addition, the progression of intima-media thickness of common carotid artery was significantly inhibited in the telmisartan group compared with the losartan group. Neither group experienced significant changes in cardiac function and LV mass index. There were no differences between the groups with respect to changes in surrogate markers such as serum adiponectin, creatinine, homeostasis model assessment index, plasminogen activator inhibitor-1 and high sensitivity C-reactive protein. Although BP levels were equal and well controlled in both groups, telmisartan showed more protective vascular effects than losartan. More... »

PAGES

1179-1184

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/hr.2011.114

DOI

http://dx.doi.org/10.1038/hr.2011.114

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1040467790

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21796128


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiotensin II Type 1 Receptor Blockers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Atherosclerosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzimidazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzoates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cardiovascular Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carotid Intima-Media Thickness", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Ventricles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertrophy, Left Ventricular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Losartan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Single-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Telmisartan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hasegawa", 
        "givenName": "Hiroshi", 
        "id": "sg:person.01371272633.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371272633.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takano", 
        "givenName": "Hiroyuki", 
        "id": "sg:person.0624235222.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624235222.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Narumi", 
        "givenName": "Hiroya", 
        "id": "sg:person.01203207133.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203207133.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Seirei Yokohama Hospital, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Cardiovascular Medicine, Seirei Yokohama Hospital, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ohtsuka", 
        "givenName": "Masashi", 
        "id": "sg:person.01075476751.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075476751.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Chiba Social Insurance Hospital, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Cardiovascular Medicine, Chiba Social Insurance Hospital, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mizuguchi", 
        "givenName": "Tadahiko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Frontier Japanese-Oriental \u2018Kampo\u2019 medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Frontier Japanese-Oriental \u2018Kampo\u2019 medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Namiki", 
        "givenName": "Takao", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kobayashi", 
        "givenName": "Yoshio", 
        "id": "sg:person.016657042642.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016657042642.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136593.b", 
          "name": [
            "Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Komuro", 
        "givenName": "Issei", 
        "id": "sg:person.01012024207.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012024207.33"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/hr.2009.34", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047258719", 
          "https://doi.org/10.1038/hr.2009.34"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1475-2840-4-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018238203", 
          "https://doi.org/10.1186/1475-2840-4-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1291/hypres.30.49", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010521145", 
          "https://doi.org/10.1291/hypres.30.49"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/hr.2009.131", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008963088", 
          "https://doi.org/10.1038/hr.2009.131"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1291/hypres.28.917", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045343815", 
          "https://doi.org/10.1291/hypres.28.917"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11906-005-0019-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033309130", 
          "https://doi.org/10.1007/s11906-005-0019-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1291/hypres.28.203", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026569557", 
          "https://doi.org/10.1291/hypres.28.203"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-07-28", 
    "datePublishedReg": "2011-07-28", 
    "description": "The Telmisartan and Losartan Cardiac Evaluation Trial, a multicenter, prospective, randomized, open-labeled, blinded-endpoint trial, was designed to compare the effects of two angiotensin II receptor blockers (ARBs), telmisartan and losartan, on cardiovascular protection in Japanese patients with mild to moderate essential hypertension. We compared the effects of telmisartan and losartan on left ventricular (LV) hypertrophy, cardiac function, atherosclerosis of carotid arteries and surrogate markers related to the actions of peroxisome proliferator-activated receptor-\u03b3. A total of 58 patients were enrolled in the present trial and the follow-up period was 1 year. There were no significant differences in blood pressure (BP) levels between the telmisartan group and the losartan group throughout the trial. The percentage of the patients treated with ARB monotherapy was significantly higher in the telmisartan group compared with the losartan group. In addition, the progression of intima-media thickness of common carotid artery was significantly inhibited in the telmisartan group compared with the losartan group. Neither group experienced significant changes in cardiac function and LV mass index. There were no differences between the groups with respect to changes in surrogate markers such as serum adiponectin, creatinine, homeostasis model assessment index, plasminogen activator inhibitor-1 and high sensitivity C-reactive protein. Although BP levels were equal and well controlled in both groups, telmisartan showed more protective vascular effects than losartan.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/hr.2011.114", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1313717", 
        "issn": [
          "0916-9636", 
          "1348-4214"
        ], 
        "name": "Hypertension Research", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "34"
      }
    ], 
    "keywords": [
      "angiotensin II receptor blockers", 
      "effects of telmisartan", 
      "telmisartan group", 
      "losartan group", 
      "cardiovascular protection", 
      "cardiac function", 
      "surrogate marker", 
      "carotid artery", 
      "high-sensitivity C-reactive protein", 
      "homeostasis model assessment index", 
      "sensitivity C-reactive protein", 
      "blinded-endpoint trial", 
      "peroxisome proliferator-activated receptor", 
      "moderate essential hypertension", 
      "II receptor blockers", 
      "LV mass index", 
      "model assessment index", 
      "Japanese hypertensive patients", 
      "blood pressure levels", 
      "left ventricular hypertrophy", 
      "intima-media thickness", 
      "C-reactive protein", 
      "plasminogen activator inhibitor-1", 
      "protective vascular effects", 
      "common carotid artery", 
      "proliferator-activated receptor", 
      "activator inhibitor-1", 
      "ARB monotherapy", 
      "receptor blockers", 
      "hypertensive patients", 
      "serum adiponectin", 
      "vascular effects", 
      "essential hypertension", 
      "ventricular hypertrophy", 
      "BP levels", 
      "mass index", 
      "Japanese patients", 
      "losartan", 
      "present trial", 
      "patients", 
      "telmisartan", 
      "inhibitor-1", 
      "trials", 
      "significant differences", 
      "artery", 
      "significant changes", 
      "group", 
      "markers", 
      "evaluation trials", 
      "pressure levels", 
      "assessment index", 
      "multicenter", 
      "hypertension", 
      "monotherapy", 
      "adiponectin", 
      "atherosclerosis", 
      "creatinine", 
      "blockers", 
      "hypertrophy", 
      "progression", 
      "receptors", 
      "index", 
      "effect", 
      "levels", 
      "total", 
      "differences", 
      "changes", 
      "protection", 
      "years", 
      "percentage", 
      "function", 
      "period", 
      "protein", 
      "action", 
      "addition", 
      "respect", 
      "thickness"
    ], 
    "name": "Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients", 
    "pagination": "1179-1184", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1040467790"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/hr.2011.114"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21796128"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/hr.2011.114", 
      "https://app.dimensions.ai/details/publication/pub.1040467790"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_527.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/hr.2011.114"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/hr.2011.114'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/hr.2011.114'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/hr.2011.114'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/hr.2011.114'


 

This table displays all metadata directly associated to this object as RDF triples.

320 TRIPLES      22 PREDICATES      134 URIs      119 LITERALS      31 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/hr.2011.114 schema:about N014c3594c4de4ea48b8c6ae4e37e856a
2 N03ea7061dcc44feb8518844c5d80853b
3 N3367f52184844252a4d74f3a10692d32
4 N3b30b0ccc5644204bc6d60dc2b9e894e
5 N4645a56eaa514a9f9a73595f55c0f9e5
6 N5f8ff98ce0664b21b2966670d3396ceb
7 N6ac8e2c1edb14abfa87719c249d13da7
8 N6d3b6f9757ea43b98cc8ba5416dfc6be
9 N7757719d31d646de82a38bbccfee7ebb
10 N79cc0093f3e54b7799170d89ee9cbb42
11 N7aaea813e9fd462f86bb4fe0ba91efd0
12 N7b763d0a61c541c2bdc7aae3a60e7476
13 N7d7f2526366049699e95668d208c298a
14 N8d3f7c937eb545808ec4b67218519e6d
15 Naa0d85eb60c44055b5807a459a174a69
16 Nacd3831c633e4992b9c4375621f849cf
17 Nb9b8d10b879b4f1abb1cab15ad587db0
18 Nc52ac01e6b884d9091aa6e313c766027
19 Ncadd28e4ee1c4bddafb6ef8673d2688c
20 Nd612f0075aaf4f299336ea95bbdc4d09
21 Nd8119cedb1e540beb63220c134137edb
22 Ndd2b56c5eb3741fc8b794e1f891bd6fd
23 Nf5de112e5ff34298bd3acdea17e31cde
24 Nfb703bb31ac44a7bbf1af47180efadba
25 anzsrc-for:11
26 anzsrc-for:1102
27 schema:author N911c7e032f854ce9ac8be2e72d326135
28 schema:citation sg:pub.10.1007/s11906-005-0019-y
29 sg:pub.10.1038/hr.2009.131
30 sg:pub.10.1038/hr.2009.34
31 sg:pub.10.1186/1475-2840-4-6
32 sg:pub.10.1291/hypres.28.203
33 sg:pub.10.1291/hypres.28.917
34 sg:pub.10.1291/hypres.30.49
35 schema:datePublished 2011-07-28
36 schema:datePublishedReg 2011-07-28
37 schema:description The Telmisartan and Losartan Cardiac Evaluation Trial, a multicenter, prospective, randomized, open-labeled, blinded-endpoint trial, was designed to compare the effects of two angiotensin II receptor blockers (ARBs), telmisartan and losartan, on cardiovascular protection in Japanese patients with mild to moderate essential hypertension. We compared the effects of telmisartan and losartan on left ventricular (LV) hypertrophy, cardiac function, atherosclerosis of carotid arteries and surrogate markers related to the actions of peroxisome proliferator-activated receptor-γ. A total of 58 patients were enrolled in the present trial and the follow-up period was 1 year. There were no significant differences in blood pressure (BP) levels between the telmisartan group and the losartan group throughout the trial. The percentage of the patients treated with ARB monotherapy was significantly higher in the telmisartan group compared with the losartan group. In addition, the progression of intima-media thickness of common carotid artery was significantly inhibited in the telmisartan group compared with the losartan group. Neither group experienced significant changes in cardiac function and LV mass index. There were no differences between the groups with respect to changes in surrogate markers such as serum adiponectin, creatinine, homeostasis model assessment index, plasminogen activator inhibitor-1 and high sensitivity C-reactive protein. Although BP levels were equal and well controlled in both groups, telmisartan showed more protective vascular effects than losartan.
38 schema:genre article
39 schema:inLanguage en
40 schema:isAccessibleForFree true
41 schema:isPartOf Na256f9f764a449509655b891e45429f2
42 Ne7fe3077fe534a40abc2df5792d2b920
43 sg:journal.1313717
44 schema:keywords ARB monotherapy
45 BP levels
46 C-reactive protein
47 II receptor blockers
48 Japanese hypertensive patients
49 Japanese patients
50 LV mass index
51 action
52 activator inhibitor-1
53 addition
54 adiponectin
55 angiotensin II receptor blockers
56 artery
57 assessment index
58 atherosclerosis
59 blinded-endpoint trial
60 blockers
61 blood pressure levels
62 cardiac function
63 cardiovascular protection
64 carotid artery
65 changes
66 common carotid artery
67 creatinine
68 differences
69 effect
70 effects of telmisartan
71 essential hypertension
72 evaluation trials
73 function
74 group
75 high-sensitivity C-reactive protein
76 homeostasis model assessment index
77 hypertension
78 hypertensive patients
79 hypertrophy
80 index
81 inhibitor-1
82 intima-media thickness
83 left ventricular hypertrophy
84 levels
85 losartan
86 losartan group
87 markers
88 mass index
89 model assessment index
90 moderate essential hypertension
91 monotherapy
92 multicenter
93 patients
94 percentage
95 period
96 peroxisome proliferator-activated receptor
97 plasminogen activator inhibitor-1
98 present trial
99 pressure levels
100 progression
101 proliferator-activated receptor
102 protection
103 protective vascular effects
104 protein
105 receptor blockers
106 receptors
107 respect
108 sensitivity C-reactive protein
109 serum adiponectin
110 significant changes
111 significant differences
112 surrogate marker
113 telmisartan
114 telmisartan group
115 thickness
116 total
117 trials
118 vascular effects
119 ventricular hypertrophy
120 years
121 schema:name Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients
122 schema:pagination 1179-1184
123 schema:productId N261874ae240345e6b1822d0fa0e16759
124 Ne1ae7a96c1224b56ae2161f219bc67f5
125 Nef7ac7c20cd7474d87e1e62d9c41eced
126 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040467790
127 https://doi.org/10.1038/hr.2011.114
128 schema:sdDatePublished 2022-05-20T07:26
129 schema:sdLicense https://scigraph.springernature.com/explorer/license/
130 schema:sdPublisher N2d7b7797d5a74315bda6c0b3ffe4debc
131 schema:url https://doi.org/10.1038/hr.2011.114
132 sgo:license sg:explorer/license/
133 sgo:sdDataset articles
134 rdf:type schema:ScholarlyArticle
135 N014c3594c4de4ea48b8c6ae4e37e856a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Severity of Illness Index
137 rdf:type schema:DefinedTerm
138 N03ea7061dcc44feb8518844c5d80853b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Humans
140 rdf:type schema:DefinedTerm
141 N11f62d44178f477984b7c34189a9fbfe rdf:first sg:person.01203207133.99
142 rdf:rest Nbbce6103382440c6a16a5e898275a7d2
143 N18812676529643609b4901052cf8f4ae rdf:first sg:person.01012024207.33
144 rdf:rest rdf:nil
145 N2045101ef4804c8d9936f83b8f9d6cb1 rdf:first sg:person.0624235222.83
146 rdf:rest N11f62d44178f477984b7c34189a9fbfe
147 N261874ae240345e6b1822d0fa0e16759 schema:name doi
148 schema:value 10.1038/hr.2011.114
149 rdf:type schema:PropertyValue
150 N2d7b7797d5a74315bda6c0b3ffe4debc schema:name Springer Nature - SN SciGraph project
151 rdf:type schema:Organization
152 N3367f52184844252a4d74f3a10692d32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Male
154 rdf:type schema:DefinedTerm
155 N3b30b0ccc5644204bc6d60dc2b9e894e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Risk Factors
157 rdf:type schema:DefinedTerm
158 N431378b773b84c5596489cdc5ffe3f53 rdf:first Neba8e9633954442a9c40aad53ea85691
159 rdf:rest N47cf13cdf8a040b7b45e7a7c170a8de6
160 N4645a56eaa514a9f9a73595f55c0f9e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Losartan
162 rdf:type schema:DefinedTerm
163 N47cf13cdf8a040b7b45e7a7c170a8de6 rdf:first N50d9549a6644475492b0b6d8649deb1d
164 rdf:rest N8e1659b900204536882fa01299db9812
165 N50d9549a6644475492b0b6d8649deb1d schema:affiliation grid-institutes:grid.136304.3
166 schema:familyName Namiki
167 schema:givenName Takao
168 rdf:type schema:Person
169 N5f8ff98ce0664b21b2966670d3396ceb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Female
171 rdf:type schema:DefinedTerm
172 N6ac8e2c1edb14abfa87719c249d13da7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Hypertrophy, Left Ventricular
174 rdf:type schema:DefinedTerm
175 N6d3b6f9757ea43b98cc8ba5416dfc6be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Middle Aged
177 rdf:type schema:DefinedTerm
178 N7757719d31d646de82a38bbccfee7ebb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Single-Blind Method
180 rdf:type schema:DefinedTerm
181 N79cc0093f3e54b7799170d89ee9cbb42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Carotid Intima-Media Thickness
183 rdf:type schema:DefinedTerm
184 N7aaea813e9fd462f86bb4fe0ba91efd0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Atherosclerosis
186 rdf:type schema:DefinedTerm
187 N7b763d0a61c541c2bdc7aae3a60e7476 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Aged
189 rdf:type schema:DefinedTerm
190 N7d7f2526366049699e95668d208c298a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Prospective Studies
192 rdf:type schema:DefinedTerm
193 N8d3f7c937eb545808ec4b67218519e6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Japan
195 rdf:type schema:DefinedTerm
196 N8e1659b900204536882fa01299db9812 rdf:first sg:person.016657042642.17
197 rdf:rest N18812676529643609b4901052cf8f4ae
198 N911c7e032f854ce9ac8be2e72d326135 rdf:first sg:person.01371272633.17
199 rdf:rest N2045101ef4804c8d9936f83b8f9d6cb1
200 Na256f9f764a449509655b891e45429f2 schema:volumeNumber 34
201 rdf:type schema:PublicationVolume
202 Naa0d85eb60c44055b5807a459a174a69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Heart Ventricles
204 rdf:type schema:DefinedTerm
205 Nacd3831c633e4992b9c4375621f849cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Hypertension
207 rdf:type schema:DefinedTerm
208 Nb9b8d10b879b4f1abb1cab15ad587db0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Benzimidazoles
210 rdf:type schema:DefinedTerm
211 Nbbce6103382440c6a16a5e898275a7d2 rdf:first sg:person.01075476751.12
212 rdf:rest N431378b773b84c5596489cdc5ffe3f53
213 Nc52ac01e6b884d9091aa6e313c766027 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Benzoates
215 rdf:type schema:DefinedTerm
216 Ncadd28e4ee1c4bddafb6ef8673d2688c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Treatment Outcome
218 rdf:type schema:DefinedTerm
219 Nd612f0075aaf4f299336ea95bbdc4d09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Cardiovascular Diseases
221 rdf:type schema:DefinedTerm
222 Nd8119cedb1e540beb63220c134137edb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
223 schema:name Adult
224 rdf:type schema:DefinedTerm
225 Ndd2b56c5eb3741fc8b794e1f891bd6fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
226 schema:name Follow-Up Studies
227 rdf:type schema:DefinedTerm
228 Ne1ae7a96c1224b56ae2161f219bc67f5 schema:name pubmed_id
229 schema:value 21796128
230 rdf:type schema:PropertyValue
231 Ne7fe3077fe534a40abc2df5792d2b920 schema:issueNumber 11
232 rdf:type schema:PublicationIssue
233 Neba8e9633954442a9c40aad53ea85691 schema:affiliation grid-institutes:None
234 schema:familyName Mizuguchi
235 schema:givenName Tadahiko
236 rdf:type schema:Person
237 Nef7ac7c20cd7474d87e1e62d9c41eced schema:name dimensions_id
238 schema:value pub.1040467790
239 rdf:type schema:PropertyValue
240 Nf5de112e5ff34298bd3acdea17e31cde schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
241 schema:name Telmisartan
242 rdf:type schema:DefinedTerm
243 Nfb703bb31ac44a7bbf1af47180efadba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
244 schema:name Angiotensin II Type 1 Receptor Blockers
245 rdf:type schema:DefinedTerm
246 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
247 schema:name Medical and Health Sciences
248 rdf:type schema:DefinedTerm
249 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
250 schema:name Cardiorespiratory Medicine and Haematology
251 rdf:type schema:DefinedTerm
252 sg:journal.1313717 schema:issn 0916-9636
253 1348-4214
254 schema:name Hypertension Research
255 schema:publisher Springer Nature
256 rdf:type schema:Periodical
257 sg:person.01012024207.33 schema:affiliation grid-institutes:grid.136593.b
258 schema:familyName Komuro
259 schema:givenName Issei
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012024207.33
261 rdf:type schema:Person
262 sg:person.01075476751.12 schema:affiliation grid-institutes:None
263 schema:familyName Ohtsuka
264 schema:givenName Masashi
265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075476751.12
266 rdf:type schema:Person
267 sg:person.01203207133.99 schema:affiliation grid-institutes:grid.136304.3
268 schema:familyName Narumi
269 schema:givenName Hiroya
270 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203207133.99
271 rdf:type schema:Person
272 sg:person.01371272633.17 schema:affiliation grid-institutes:grid.136304.3
273 schema:familyName Hasegawa
274 schema:givenName Hiroshi
275 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371272633.17
276 rdf:type schema:Person
277 sg:person.016657042642.17 schema:affiliation grid-institutes:grid.136304.3
278 schema:familyName Kobayashi
279 schema:givenName Yoshio
280 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016657042642.17
281 rdf:type schema:Person
282 sg:person.0624235222.83 schema:affiliation grid-institutes:grid.136304.3
283 schema:familyName Takano
284 schema:givenName Hiroyuki
285 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0624235222.83
286 rdf:type schema:Person
287 sg:pub.10.1007/s11906-005-0019-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1033309130
288 https://doi.org/10.1007/s11906-005-0019-y
289 rdf:type schema:CreativeWork
290 sg:pub.10.1038/hr.2009.131 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008963088
291 https://doi.org/10.1038/hr.2009.131
292 rdf:type schema:CreativeWork
293 sg:pub.10.1038/hr.2009.34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047258719
294 https://doi.org/10.1038/hr.2009.34
295 rdf:type schema:CreativeWork
296 sg:pub.10.1186/1475-2840-4-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018238203
297 https://doi.org/10.1186/1475-2840-4-6
298 rdf:type schema:CreativeWork
299 sg:pub.10.1291/hypres.28.203 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026569557
300 https://doi.org/10.1291/hypres.28.203
301 rdf:type schema:CreativeWork
302 sg:pub.10.1291/hypres.28.917 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045343815
303 https://doi.org/10.1291/hypres.28.917
304 rdf:type schema:CreativeWork
305 sg:pub.10.1291/hypres.30.49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010521145
306 https://doi.org/10.1291/hypres.30.49
307 rdf:type schema:CreativeWork
308 grid-institutes:None schema:alternateName Department of Cardiovascular Medicine, Chiba Social Insurance Hospital, Chiba, Japan
309 Department of Cardiovascular Medicine, Seirei Yokohama Hospital, Yokohama, Japan
310 schema:name Department of Cardiovascular Medicine, Chiba Social Insurance Hospital, Chiba, Japan
311 Department of Cardiovascular Medicine, Seirei Yokohama Hospital, Yokohama, Japan
312 rdf:type schema:Organization
313 grid-institutes:grid.136304.3 schema:alternateName Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
314 Department of Frontier Japanese-Oriental ‘Kampo’ medicine, Chiba University Graduate School of Medicine, Chiba, Japan
315 schema:name Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
316 Department of Frontier Japanese-Oriental ‘Kampo’ medicine, Chiba University Graduate School of Medicine, Chiba, Japan
317 rdf:type schema:Organization
318 grid-institutes:grid.136593.b schema:alternateName Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
319 schema:name Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan
320 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...